By Jonathan Gardner | Published October 8, 2026
In a move designed to fortify its position in the non-opioid pain management market, Viatris announced today that it has successfully acquired a suite of commercial assets from Pacira BioSciences. The deal, which brings two prominent non-opioid analgesics into the Viatris fold, underscores the Pittsburgh-based pharmaceutical giant’s ongoing strategy of aggressive capital deployment and the acquisition of established, high-performing commercial assets.
The two products at the center of the transaction—Exparel, a post-surgical anesthetic, and Zilretta, a treatment for knee pain associated with osteoarthritis—generated nearly $700 million in revenue during 2025. While the acquisition provides an immediate boost to the company’s bottom line, it also invites complex questions regarding long-term patent strategy and the looming threat of generic competition.
Main Facts: The Strategic Rationale
The acquisition represents a calculated gamble for Viatris. By absorbing Exparel and Zilretta, the company is not merely adding revenue; it is diversifying a pain-management portfolio that already includes established heavyweights like Celebrex and Relpax.
For Viatris, the appeal lies in the synergy between these products and its existing infrastructure. Viatris has long prioritized the acquisition of "on-market, commercial assets"—a strategy praised by Leerink analyst Daniel Clark, who noted that the deal is expected to be "immediately accretive" to revenue. By integrating these assets, Viatris aims to leverage its global supply chain and regulatory expertise to sustain growth well into the 2030s.
However, the acquisition is not without its hurdles. Both products are effectively sophisticated, proprietary formulations of older, off-patent compounds. Exparel is a long-acting liposomal formulation of the local anesthetic bupivacaine, while Zilretta utilizes an extended-release microsphere technology for the steroid triamcinolone. As these formulations approach their respective patent cliffs, Viatris will be tasked with defending its market share against generic entrants seeking to challenge the validity of its intellectual property.
Chronology of Developments
The path to this acquisition has been marked by a series of legal and commercial milestones that have defined the current landscape for both companies:
- 2024: Pacira successfully secured significant manufacturing patents for Exparel, effectively pushing the drug’s intellectual property protections toward a 2044 horizon, according to the FDA’s Orange Book. This move was intended to solidify its market exclusivity in the face of mounting generic pressure.
- 2025: Throughout the fiscal year, Exparel and Zilretta combined to generate nearly $700 million in U.S. revenue. Despite this performance, growth for Exparel remained somewhat stagnant due to the hesitation of hospital formularies to adopt new, premium-priced post-surgical protocols.
- Late 2025: Pacira entered into critical patent settlements with Fresenius Kabi and a subsidiary of Hengrui Pharma. These agreements established a timeline for the entry of generic competition, allowing these manufacturers to introduce a "high single digit" percentage of total U.S. volume, eventually scaling to 30% within three years of the settlement date.
- September 2026: Leerink analyst Daniel Clark initiated coverage on Pacira, noting that while the drug had recently secured coverage from United Healthcare, its growth ceiling was likely capped by the existing hospital-procurement environment.
- October 8, 2026: Viatris officially confirms the acquisition, signaling a new chapter for the assets and a shift in its corporate capital allocation strategy.
Supporting Data and Financial Outlook
The financial logic driving the acquisition is rooted in the "accretive" nature of the assets. Analysts project that by adding these high-margin treatments, Viatris will see sustained earnings growth through the end of the decade.
However, the data also highlights the fragility of this growth. According to the FDA, the patents covering Zilretta are firmly set to expire in 2031, leaving Viatris with a relatively short window to maximize returns before generic versions enter the market.
Exparel’s situation is more complex. While the 2024 manufacturing patents theoretically extend protection until 2044, they are currently under fire. Two additional manufacturers have filed challenges, arguing that the underlying innovations do not merit such extended exclusivity. If these challenges prove successful, the "steady source of growth" that Viatris is counting on could be disrupted significantly sooner than the 2044 date suggests.
Official Responses and Corporate Strategy
Viatris has been characteristically confident regarding the integration of these assets. In a statement released Thursday, the company emphasized its "intellectual property expertise" and its "proven ability to extend product lifecycles."
"We are committed to sustaining meaningful sales after generic entry," a Viatris spokesperson noted. This strategy often involves shifting marketing focus, optimizing manufacturing costs, and potentially exploring "authorized generic" agreements that allow Viatris to capture a portion of the market even after the exclusivity period ends.
Pacira, for its part, appears to be pivoting toward a more streamlined business model, potentially freeing up resources for R&D in other therapeutic areas. By offloading these assets to a larger player with deeper commercial reach, Pacira ensures that the products continue to reach patients while offloading the heavy burden of litigation and global distribution.
Implications for the Pain Management Market
The acquisition carries significant implications for the broader pharmaceutical sector, particularly in the non-opioid space. As the healthcare industry continues to move away from addictive opioid-based pain protocols, there is an increasing demand for sophisticated, long-acting non-opioid alternatives.
1. Market Consolidation
The deal reflects a broader trend of consolidation in the specialty pharmaceutical space. Larger, diversified companies like Viatris are increasingly scooping up niche, high-value assets from mid-cap biotech firms that may lack the commercial muscle to navigate complex formulary negotiations with major insurers like United Healthcare.
2. The "Formulary Barrier"
The growth of these drugs is no longer just about clinical efficacy; it is about procurement. As the industry observed with Exparel, winning clinical approval is only half the battle. The real struggle lies in convincing hospital procurement committees that the cost of a premium, long-acting drug is offset by the reduction in secondary complications and the shorter recovery times associated with reduced opioid usage. Viatris’s ability to secure better formulary access could be the "X-factor" that determines the success of this acquisition.
3. The Future of Patent Litigation
This transaction serves as a bellwether for how the industry handles the "patent cliff." By acquiring assets that are already in the midst of complex litigation, Viatris is demonstrating a high risk-tolerance for legal uncertainty. Investors will be watching closely to see if Viatris can successfully defend the 2044 Exparel patents or if the company will be forced to negotiate further settlements with the remaining challengers.
4. Awaiting the Meloxicam Verdict
The deal also sets the stage for a critical end-of-year milestone. Viatris is currently awaiting an FDA decision, due by December 27, 2026, on a fast-acting version of meloxicam. Should the FDA approve this, it would provide Viatris with a three-pronged strategy in the acute pain market, potentially allowing the company to bundle these treatments for hospital systems, further entrenching its market dominance.
Conclusion
The acquisition of Pacira’s assets is a tactical move that places Viatris in the center of the non-opioid pain relief conversation. While the looming threat of generic competition and the ongoing legal challenges to its patent portfolio present significant risks, Viatris is banking on its scale, distribution power, and regulatory acumen to outlast its competitors. As the industry shifts toward more specialized, non-addictive pain management, Viatris is clearly positioning itself to be the primary provider for hospitals and clinics nationwide, provided it can successfully navigate the legal and formulary headwinds that lie ahead.
About the Author
